Colin Bristow
Stock Analyst at UBS
(1.16)
# 3,629
Out of 4,941 analysts
102
Total ratings
33.33%
Success rate
-12.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $120.02 | -6.68% | 4 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $582 → $553 | $387.77 | +42.61% | 15 | Aug 5, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $45.27 | +76.72% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $2.91 | +71.82% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $0.62 | +62.58% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $15.20 | +11.84% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $284.98 | +11.94% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.26 | +217.46% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $3.64 | +92.31% | 2 | Feb 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $24.65 | +13.59% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $80.30 | +49.44% | 6 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $128.93 | +56.67% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $6.80 | +135.29% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $556.56 | +97.46% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $18.80 | +788.30% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $639.43 | -34.32% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $4.18 | -52.15% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.24 | +703.57% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $198.64 | -26.50% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $46.55 | +61.12% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.24 | +1,060.71% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $6.35 | +41.73% | 1 | Aug 23, 2021 |
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $120.02
Upside: -6.68%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Buy
Price Target: $582 → $553
Current: $387.77
Upside: +42.61%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $45.27
Upside: +76.72%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $2.91
Upside: +71.82%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $0.62
Upside: +62.58%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $15.20
Upside: +11.84%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $284.98
Upside: +11.94%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.26
Upside: +217.46%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $3.64
Upside: +92.31%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $24.65
Upside: +13.59%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $80.30
Upside: +49.44%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $128.93
Upside: +56.67%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $6.80
Upside: +135.29%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $556.56
Upside: +97.46%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $18.80
Upside: +788.30%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $639.43
Upside: -34.32%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $4.18
Upside: -52.15%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.24
Upside: +703.57%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $198.64
Upside: -26.50%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $46.55
Upside: +61.12%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.24
Upside: +1,060.71%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $6.35
Upside: +41.73%